How CBG may help those suffering from glaucoma

The researcher of a 1990 paper, Brenda K. Colasanti, wanted to compare the ocular effects of THC and CBG to see how the matched up for helping people suffering from glaucoma.

Colasanti first tested how topical application of these cannabinoids impacted the eyes of cats. The results showed a modest drop in intraocular pressure, but nothing of clinical value.

Next, the researcher used Alzet osmotic minipumps and connecting extraocular cannulas to apply chronic administration of CBG to the cat’s eyes. This application resulted in a significant drop in intraocular pressure. In fact, ocular tension dropped by 4 to 7 mmHg, according to Colasanti.

Interestingly, the study also showed that CBG did not impact the rate at which subjects created aqueous humor. However, it did increase aqueous outflow facility by two- to three-fold.

As a result of Colasanti’s experiments, the study concluded that CBG “may have therapeutic potential for the treatment of glaucoma.”

A 2018 paper looked into the topic further and found that CBG may reduce the intraocular pressure of those with glaucoma “due to the activation of GPR18, which has been localized to the ciliary epithelium and iris.” That finding was partly based off research that was published in 2011 that looked at the pharmacological properties of an analog of CBG, CBG-DMH. The results of that study, which were published in the Journal of Ocular Pharmacology and Therapeutics mirrored the attenuating effects that CBG and its derivatives have on intraocular pressure. Afterall, CBG and its derivatives seem to have the “potential for further investigation as novel ocular hypotensive cannabinoids devoid of CB(1)R-mediated side-effects.”